Abstract:Limited success has been achieved in ferroptosis-induced cancer treatment due to the challenges related to low production of toxic reactive oxygen species (ROS) and inherent ROS resistance in cancer cells. To address this issue, a self-assembled nanodrug have been investigated that enhances ferroptosis therapy by increasing ROS production and reducing ROS inhibition. The nanodrug is constructed by allowing doxorubicin (DOX) to interact with Fe 2+ through coordination interactions, forming a stable DOX-Fe 2+ chelate, and this chelate further interacts with sorafenib (SRF), resulting in a stable and uniform nanoparticle. In tumor cells, overexpressed glutathione (GSH) triggers the disassembly of nanodrug, thereby activating the drug release. Interestingly, the released DOX not only activates nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) to produce abundant H 2 O 2 production for enhanced ROS production, but also acts as a chemotherapeutics agent, synergizing with ferroptosis. To enhance tumor selectivity and improve the blood clearance, the nanodrug is coated with a related cancer cell membrane, which enhances the selective inhibition of tumor growth and metastasis in a B16F10 mice model. Our findings provide valuable insights into the rational design of self-assembled nanodrug for enhanced ferroptosis therapy in cancer treatment. Statement of significance Ferroptosis is a non-apoptotic form of cell death induced by the iron-regulated lipid peroxides (LPOs), offering a promising potential for effective and safe anti-cancer treatment. However, two significant challenges hinder its clinical application: 1) The easily oxidized nature of Fe2+ and the low concentration of H 2 O 2 leads to a low efficiency of intracellular Fenton reaction, resulting in poor therapeutic efficacy; 2) The instinctive ROS resistance of cancer cells induce drug resistance. Therefore, we developed a simple and high-efficiency nanodrug composed of self-assembling by Fe 2+ sources, H 2 O 2 inducer and ROS resistance inhibitors. This nanodrug can effectively deliver the Fe 2+ sources into tumor tissue, enhance intracellular concentration of H2O2, and reduce ROS resistance, achieving a high-efficiency, precise and safe ferroptosis therapy.

Protein‐Gold Nanoclusters Loaded with Ferrous Ions for Inducing Ferroptosis of Hepatoma Cells

Dual GSH-exhausting Sorafenib Loaded Manganese-Silica Nanodrugs for Inducing the Ferroptosis of Hepatocellular Carcinoma Cells.

Biodegradable Ferric Phosphate Nanocarriers with Tumor‐Specific Activation and Glutathione Depletion for Tumor Self‐Enhanced Ferroptosis and Chemotherapy

Nanovesicle-templated Nanogel: A Dual-Modal Platform Integrating Intracellular Iron Homeostasis Disruption for Ferroptosis and MRI-guided Tumor Diagnosis

Multifunctional Fe 3 O 4 -PEI@HA nanoparticles in the ferroptosis treatment of hepatocellular carcinoma through modulating reactive oxygen species

Highly selective and effective ferroptosis liposomal nanodrugs for synergistic antitumor therapy

Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy

A homologous membrane-camouflaged self-assembled nanodrug for synergistic antitumor therapy

Spatially Asymmetric Nanoparticles for Boosting Ferroptosis in Tumor Therapy.

Engineered anti-cancer nanomedicine for synergistic ferroptosis-immunotherapy

GSH/Ph Dual Activatable Crosslinked And Fluorinated Pei for Cancer Gene Therapy Through Endogenous Iron De‐Hijacking And in Situ Ros Amplification

Inhibition of hepatocellular carcinoma cells through ferroptosis therapy using Fe3O4/Ag nanocomposites

Histidine phosphatase-ferroptosis crosstalk modulation for efficient hepatocellular carcinoma treatment

Integrated ferroptosis, apoptosis, and pyroptosis for liver cancer treatment by an iron single atom-graphene oxide composite

A Fe(III)-porphyrin-oxaliplatin(IV) Nanoplatform for Enhanced Ferroptosis and Combined Therapy

Cyclic Catalysis of Intratumor Fe3+/2+ Initiated by a Hollow Mesoporous Iron Sesquioxide Nanoparticle for Ferroptosis Therapy of Large Tumors

Multifunctional nanoplatform with near-infrared triggered nitric-oxide release for enhanced tumor ferroptosis

Zwitterionic Polymer Coated Sorafenib-Loaded Fe3O4 Composite Nanoparticles Induced Ferroptosis for Cancer Therapy.

Protease‐Activatable Nanozyme with Photoacoustic and Tumor‐Enhanced Magnetic Resonance Imaging for Photothermal Ferroptosis Cancer Therapy

Biodegradable zwitterionic polymer-cloaked defective metal–organic frameworks for ferroptosis-inducing cancer therapy

Ferrous-Supply-Regeneration Nanoengineering for Cancer-Cell-Specific Ferroptosis in Combination with Imaging-Guided Photodynamic Therapy.